Posted 13th February 2019 by Joshua Broomfield
I was a scientist at Los Alamos National Lab in the US when I identified a science-based personalized diet that completely cured my early onset arthritis. I realized that the gut microbiome would play a central role in personalized nutrition and redirected all my science projects towards it. We desperately needed better technology for analysing the gut microbiome and metatranscriptomics offers the best value. It is better than 16S or metagenomic sequencing in two important aspects:
Posted 16th November 2017 by Jane Williams
By any measure, momentum in the microbiome space keeps building. The 2017 Silicon Valley Bank mid-year Microbiome Investment Trends report provides one of the most up-to-date snapshots: close to USD 1 billion has been invested in microbiome companies globally since 2010, and SVB’s analysts predict the total capital in disclosed equity investments in 2017 alone could be reaching north of USD 400 million by year-end. And my own analysis of Microbiome Partnership Trends, published earlier this year, documents the dramatic increase in partnerships during 2016, a trend that has shown no signs of slowing down.